---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-041862"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2025-04-30T23:59:59+00:00"
generated_at: "2026-05-23T02:38:32.951549+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TriSalus announces $22M private placement, Q1 revenue up 42% to $9.2M

## Summary
- Private placement of 5.5M shares at $4.00/share raises ~$22M gross; led by Nantahala Capital, Broadfin Holdings. Expected close May 2, 2025.
- Preliminary Q1 2025 revenue ~$9.2M (solely from TriNav Infusion System), +42% YoY.
- Exchange offer for Series A Preferred Stock: each share exchanged for common at formula based on $10.00 liquidation preference plus accrued dividends through Aug 2027 divided by $4.00.
- Special meeting to vote on amendment allowing company to call Preferred Stock for conversion and eliminate July 2027 conversion price reset.

## SEC filing metadata
- accession: 0001104659-25-041862
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2025-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000110465925041862/0001104659-25-041862-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000110465925041862/tm2513482d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-041862
- JSON: https://secwatch.observer/filing/0001104659-25-041862.json
- Plain text: https://secwatch.observer/filing/0001104659-25-041862.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.